BRAF-KIAA1549 (Kex16Bex9)

KIAA1549-BRAF · Variant type: fusion · Fusion partner: KIAA1549 (Kex16Bex9)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Regorafenib	99.0%	1.0%	95.99
2	Vemurafenib	98.4%	1.6%	96.49
3	Sorafenib	98.2%	1.8%	96.72
4	Ponatinib	98.1%	1.9%	78.23
5	Ripretinib	97.8%	2.2%	92.95
6	Nilotinib	97.1%	2.9%	96.49
7	Dabrafenib	95.8%	4.2%	94.74
8	Encorafenib	95.5%	4.5%	98.50
9	Apatinib	92.1%	7.9%	97.73
10	Pazopanib	90.2%	9.8%	97.49
11	Dasatinib	89.1%	10.9%	87.97
12	Imatinib	66.9%	33.1%	99.00
13	Erdafitinib	56.8%	43.2%	95.71
14	Rabusertib	52.8%	47.2%	98.74
15	Umbralisib	43.1%	56.9%	98.74
16	Fostamatinib	36.0%	64.0%	96.74
17	Pacritinib	33.8%	66.2%	88.64
18	Gedatolisib	33.8%	66.3%	99.75
19	Ibrutinib	31.6%	68.4%	94.74
20	Trametinib	30.8%	69.2%	99.50
21	Dacomitinib	30.3%	69.7%	97.99
22	Osimertinib	28.3%	71.7%	97.24
23	Canertinib	27.4%	72.6%	96.49
24	Upadacitinib	27.1%	72.9%	97.98
25	Ribociclib	23.3%	76.7%	99.25

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Regorafenib	99.0%	—	—
Vemurafenib	98.4%	—	—
Sorafenib	98.2%	—	—
Ponatinib	98.1%	—	—
Ripretinib	97.8%	—	—
Nilotinib	97.1%	—	—
Dabrafenib	95.8%	—	—
Encorafenib	95.5%	—	—
Apatinib	92.1%	—	—
Pazopanib	90.2%	—	—
Dasatinib	89.1%	—	—
Imatinib	66.9%	—	—
Erdafitinib	56.8%	—	—
Rabusertib	52.8%	—	—
Umbralisib	43.1%	—	—
Fostamatinib	36.0%	—	—
Pacritinib	33.8%	—	—
Gedatolisib	33.8%	—	—
Ibrutinib	31.6%	—	—
Trametinib	30.8%	—	—
Dacomitinib	30.3%	—	—
Osimertinib	28.3%	—	—
Canertinib	27.4%	—	—
Upadacitinib	27.1%	—	—
Ribociclib	23.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.7ms